Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-01-15
2010-11-09
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S424000, C544S256000, C548S550000
Reexamination Certificate
active
07829571
ABSTRACT:
The present application describes modulators of MCP-1 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
REFERENCES:
patent: 6706712 (2004-03-01), Cherney
patent: 7230133 (2004-11-01), Carter
patent: 6974836 (2005-12-01), Carter et al.
patent: 7087604 (2006-08-01), Cherney
patent: 7157470 (2007-01-01), Smallheer et al.
patent: 7163937 (2007-01-01), Carter et al.
patent: 7183270 (2007-02-01), Cherney et al.
patent: 7291615 (2007-11-01), Cherney
patent: 7317019 (2008-01-01), Carter
patent: 7338975 (2008-03-01), Carter et al.
patent: 7378409 (2008-05-01), Carter et al.
patent: 7482335 (2009-01-01), Carter et al.
patent: 2003/0171218 (2003-09-01), Bojack et al.
patent: 2005/0043392 (2005-02-01), Carter
patent: 812551 (1951-09-01), None
patent: 550924 (1993-07-01), None
patent: 63083082 (1988-04-01), None
patent: WO 97/05111 (1997-02-01), None
patent: WO 97/43257 (1997-11-01), None
patent: WO 98/01426 (1998-01-01), None
patent: WO 99/00362 (1999-01-01), None
patent: WO 99/07678 (1999-02-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 99/38844 (1999-08-01), None
patent: WO 99/40914 (1999-08-01), None
patent: WO 01/10799 (2001-02-01), None
patent: WO 01/17992 (2001-03-01), None
patent: WO 01/74783 (2001-10-01), None
patent: WO 01/74784 (2001-10-01), None
patent: WO 02/04416 (2002-01-01), None
patent: WO 02/060859 (2002-08-01), None
patent: WO 02/078679 (2002-10-01), None
patent: WO 02/102372 (2002-12-01), None
patent: WO 03/005824 (2003-01-01), None
patent: WO 2004/022536 (2004-03-01), None
patent: WO 2004/071460 (2004-08-01), None
patent: WO 2004/098516 (2004-11-01), None
Trivedl et al., “Chapter 17, Chemokines: Targets for Novel Therapeutics”, Annual Reports in Medicinal Chemistry, vol. 35, pp. 191-200, 2000.
Evans et al., “Synthesis and Dopamine Receptor Modulating Activity of Novel Peptidomimetics of t-Prolyl-t-leucyl-glycinamide Featuring α,α-Disubstituted Amino Acids”, J. Med. Chem., vol. 42, pp. 1441-1447, 1999.
Costain et al., “Modulatory Effects of PLG and its Peptidomimetics on Haloperidol-induced Catalepsy in Rats”, Peptides, vol. 20, pp. 761-767, 1999.
Walton et al., “Search for New Analgesics. Part I. Homologues of Pethidine and Related Compounds”, Journal of the Chemical Society, pp. 315-319, 1945.
Batt Douglas G.
Carter Percy H.
Cherney Robert J.
Duncia John V.
Gardner Daniel S.
Bogie Terence J.
Bristol--Myers Squibb Company
Kosack Joseph R
LandOfFree
Cyclic derivatives as modulators of chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic derivatives as modulators of chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic derivatives as modulators of chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202114